BRPI0813269A2 - Inibidores de hiv transcriptase reversa - Google Patents

Inibidores de hiv transcriptase reversa

Info

Publication number: BRPI0813269A2
Authority: BR; Brazil
Prior art keywords: transcriptase inhibitors; reverse hiv; hiv transcriptase; reverse; inhibitors
Prior art date: 2007-06-29

Application number

BRPI0813269-0A2A

Other languages

English (en)

Inventor

Hongyan Guo

Choung U Kim

Young Lee Iii

Michael L Mitchell

Gerry Rhodes

Jong Chan Son

Lianhong Xu

Original Assignee

Korean Res Inst Of Chemical Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-29

Filing date

2008-06-26

Publication date

2014-12-30

2008-06-26 Application filed by Korean Res Inst Of Chemical Technology filed Critical Korean Res Inst Of Chemical Technology

2014-12-30 Publication of BRPI0813269A2 publication Critical patent/BRPI0813269A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

BRPI0813269-0A2A 2007-06-29 2008-06-26 Inibidores de hiv transcriptase reversa BRPI0813269A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US93775607P	2007-06-29	2007-06-29
US95967607P	2007-07-16	2007-07-16
PCT/US2008/007925 WO2009005674A2 (en)	2007-06-29	2008-06-26	Novel hiv reverse transcriptase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0813269A2 true BRPI0813269A2 (pt)	2014-12-30

Family

ID=39790161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0813269-0A2A BRPI0813269A2 (pt)	2007-06-29	2008-06-26	Inibidores de hiv transcriptase reversa

Country Status (15)

Country	Link
US (2)	US8334295B2 (pt)
EP (1)	EP2167476B1 (pt)
JP (1)	JP2010532350A (pt)
KR (1)	KR101551238B1 (pt)
CN (1)	CN101784532B (pt)
AR (1)	AR067181A1 (pt)
AU (1)	AU2008271114A1 (pt)
BR (1)	BRPI0813269A2 (pt)
CA (1)	CA2692460A1 (pt)
EA (1)	EA200971115A1 (pt)
ES (1)	ES2533863T3 (pt)
MX (1)	MX2009013804A (pt)
TW (1)	TW200918507A (pt)
WO (1)	WO2009005674A2 (pt)
ZA (1)	ZA201000023B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP2514A (en) *	2006-07-24	2012-11-23	Korea Res Inst Chem Tech	HIV reverse transcriptase inhibitors
WO2009005693A1 (en) *	2007-06-29	2009-01-08	Gilead Sciences, Inc.	Novel hiv reverse transcriptase inhibitors
US8119800B2 (en)	2007-12-21	2012-02-21	Korea Research Institute Of Chemical Technology	Processes for preparing HIV reverse transcriptase inhibitors
EP2277878B1 (en) *	2008-04-10	2014-09-17	Hamari Chemicals, Ltd.	Process for production of ethynylthymidine compound using 5-methyluridine as starting raw material
KR20110112844A (ko)	2009-01-26	2011-10-13	한국화학연구원	Ｈｉｖ 역전사효소 억제제의 제조 방법
US8921415B2 (en)	2009-01-29	2014-12-30	Mapi Pharma Ltd.	Polymorphs of darunavir
HUE026849T2 (en)	2010-01-27	2016-08-29	Viiv Healthcare Company Corp Service Company	Therapeutic combination containing dolutegravir, abacavir and lamivudine
EP2528923B1 (en)	2010-01-28	2014-07-30	Mapi Pharma Limited	Process for the preparation of darunavir and darunavir intermediates
KR101650262B1 (ko)	2011-11-11	2016-08-22	화이자 인코포레이티드	2-티오피리미딘온
EP2852583A1 (en)	2012-05-23	2015-04-01	Bristol-Myers Squibb Company	Sulfilimine and sulphoxide methods for producing festinavir
TWI608102B (zh) *	2013-01-08	2017-12-11	健臻公司	iNOS抑制劑於病毒培養中增加病毒產量之用途
US20160060252A1 (en)	2013-04-16	2016-03-03	Bristol-Myers Squibb Company	5-methyluridine method for producing festinavir
WO2014201122A1 (en)	2013-06-13	2014-12-18	Bristol-Myers Squibb Company	Tert-butyl-sulphoxide method for producing festinavir
DK3236972T3 (en)	2014-12-26	2021-10-04	Univ Emory	Antivirale N4-hydroxycytidin-derivativer
CR20170498A (es)	2015-05-05	2018-01-26	Pfizer	2-tiopirimidinonas
US20180334453A1 (en)	2015-12-04	2018-11-22	Viiv Healthcare Uk Limited	Isoindoline derivatives
WO2017158151A1 (en)	2016-03-18	2017-09-21	Savira Pharmaceuticals Gmbh	Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP2020500838A (ja) *	2016-10-14	2020-01-16	ティエエッセファルマソチエタレスポンサビリタリミタータ	Α−アミノ−β−カルボキシムコン酸セミアルデヒドデカルボキシラーゼの阻害剤
CN106831608A (zh) *	2017-02-16	2017-06-13	江苏艾迪药业有限公司	一种化合物的新晶型及其制备方法与应用
BR112020010581A2 (pt)	2017-12-07	2020-11-10	Emory University	composição farmacêutica, recipiente pressurizado, e, métodos para tratar ou prevenir uma infecção viral e de tratamento ou prevenção de coronavírus humano, sars, coronavírus mers, vírus da encefalite equina oriental, vírus da encefalite equina ocidental, vírus da encefalite equina venezuelana, vírus chikungunya e infecção por infecção de ross river, vírus orthomyxoviridae ou vírus paramyxoviridae ou vírus rsv, ou infecção pelo vírus influenza a e vírus influenza b ou vírus filoviridae ou vírus ebola.
KR20210137434A (ko)	2019-01-25	2021-11-17	브라운 유니버시티	연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
US12083099B2 (en)	2020-10-28	2024-09-10	Accencio LLC	Methods of treating symptoms of coronavirus infection with viral protease inhibitors
GB202202297D0 (en)	2022-02-21	2022-04-06	Verona Pharma Plc	Formulation production process
CN115536596A (zh) *	2022-11-08	2022-12-30	巨鑫生物制药股份有限公司	一种acc007中间体的制备方法
CN116640068A (zh) *	2023-05-26	2023-08-25	康化（上海）新药研发有限公司	一种（3-环丙基-2-炔-1-基）甘氨酸苄酯的合成方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2126148A1 (en) *	1971-05-26	1972-12-07	Farbenfabriken Bayer Ag, 5090 Leverkusen	Prepn of uracil derivs - useful as plant - protection agents and their inters
DE2142317A1 (de) *	1971-08-24	1973-03-01	Bayer Ag	Hypnotisches mittel
US4656209A (en)	1982-05-26	1987-04-07	Ciba-Geigy Corporation	Chlorinated thermoplastics stabilized with aminouracils
JPS59201057A (ja)	1983-04-18	1984-11-14	Fuji Photo Film Co Ltd	ハロゲン化銀写真感光材料
US4649142A (en) *	1984-06-25	1987-03-10	Fujisawa Pharmaceutical Co., Ltd.	3,4-dihydro-1,3-disubstituted-6-(substituted phenylimino)-2(1H)-pyrimidinone useful as cardiotonic agent and anti-allergic agent
CA1334535C (en)	1988-03-31	1995-02-21	Tadashi Miyasaka	6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
WO1989010701A1 (en)	1988-05-05	1989-11-16	Basf Aktiengesellschaft	Substances based on uracil-derivates for stimulating growth and reducing fat in animals
US5219869A (en)	1989-05-17	1993-06-15	Nihon Bayer Agrochem K.K.	Nitro-substituted heterocyclic compounds
JPH0751567B2 (ja) *	1989-09-29	1995-06-05	三菱化学株式会社	６―置換アシクロピリミジンヌクレオシド誘導体及び該誘導体を有効成分とする抗ウイルス剤
KR0155168B1 (ko)	1989-09-29	1998-11-16	미우라 아끼라	6-치환된 아시클로피리미딘 뉴클레오시드 유도체 및 이를 활성성분으로 함유하는 항비루스제
EP0442473B1 (en)	1990-02-15	1998-08-19	Takeda Chemical Industries, Ltd.	Pyrimidinedione derivatives, their production and use
JP2860689B2 (ja)	1990-03-14	1999-02-24	第一製薬株式会社	ピリミジン誘導体
DE69126469T2 (de)	1990-03-29	1998-01-29	Mitsubishi Chem Corp	Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
EP0539588A1 (en)	1990-07-05	1993-05-05	Nippon Soda Co., Ltd.	Amine derivative
JPH04166931A (ja)	1990-10-31	1992-06-12	Fuji Photo Film Co Ltd	ハロゲン化銀写真感光材料
JPH04166930A (ja)	1990-10-31	1992-06-12	Fuji Photo Film Co Ltd	ハロゲン化銀写真感光材料
JP2739260B2 (ja)	1991-04-10	1998-04-15	富士写真フイルム株式会社	ハロゲン化銀写真感光材料
AU1994492A (en)	1991-07-22	1993-02-23	Baker Cummins Pharmaceuticals, Inc.	Acyclic 6-phenylselenenyl pyrimidine nucleosides
DE4204031A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
DE4204032A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
JPH05289238A (ja)	1992-04-08	1993-11-05	Fuji Photo Film Co Ltd	ハロゲン化銀写真感光材料
JPH06135943A (ja)	1992-09-14	1994-05-17	Japan Energy Corp	新規なウラシル誘導体及びそれを有効成分とするアレルギー疾患治療薬
AU6643694A (en) *	1993-05-21	1994-12-20	Pentapharm Ag	3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones
EP0631783A1 (en)	1993-06-03	1995-01-04	Mitsubishi Chemical Corporation	Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
CA2133355A1 (en)	1993-10-04	1995-04-05	Itaru Nitta	Method for producing polypeptide
KR0151811B1 (ko)	1993-12-21	1998-10-15	강박광	신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법
BR9408370A (pt)	1994-02-28	1997-08-26	Sunkyong Ind Ltd	Derivados aciclonucleosídeo de pirimidina
JP3264579B2 (ja)	1994-03-18	2002-03-11	扶桑薬品工業株式会社	クラミジア・トラコマチス血清型の鑑別法
JPH083143A (ja)	1994-06-21	1996-01-09	Mitsubishi Chem Corp	６−アラルキル置換ピリミジン誘導体の製造方法
DE19505168A1 (de)	1995-02-16	1996-08-22	Boehringer Mannheim Gmbh	Spezifische Lipidkonjugate von Nucleosid-Diphosphonaten und deren Verwendung als Arzneimittel
US6174998B1 (en)	1996-03-12	2001-01-16	Roche Diagnostics Gmbh	C-nucleoside derivatives and their use in the detection of nucleic acids
JPH0920792A (ja)	1995-07-11	1997-01-21	Soyaku Gijutsu Kenkyusho:Kk	ヌクレオチドダイマー
EP0827498B1 (en)	1996-02-22	2003-06-18	Samjin Pharmaceutical Co., Ltd.	New antiviral substituted pyrimidinedione homocarbocyclic nucleoside derivatives and methods for the preparation thereof and compositions containing the same as active ingredients
KR100219922B1 (ko) *	1996-05-16	1999-09-01	이서봉	신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
JPH10130245A (ja)	1996-09-06	1998-05-19	Mitsubishi Chem Corp	アシクロヌクレオシドの製造方法
JPH10130244A (ja)	1996-09-06	1998-05-19	Mitsubishi Chem Corp	アシクロヌクレオシドの製造方法
MY114466A (en)	1996-09-25	2002-10-31	Crompton Vinyl Additives Gmbh	Rigid pvc stabilised with n, n-dimethyl-6-aminouracils
JPH10168068A (ja)	1996-12-05	1998-06-23	Mitsubishi Chem Corp	アシクロヌクレオシドの製造方法
ZA98566B (en)	1997-01-31	1998-07-30	Mitsubishi Chem Corp	Antiviral agents
JPH11102047A (ja)	1997-09-26	1999-04-13	Fuji Photo Film Co Ltd	熱現像画像形成材料
US5998411A (en) *	1998-03-17	1999-12-07	Hughes Institute	Heterocyclic nonnucleoside inhibitors of reverse transcriptase
FR2779721A1 (fr)	1998-06-15	1999-12-17	Expansia Sa	Substitution d'une 1,5-dialkyl uracile en position 6
FR2779722A1 (fr)	1998-06-15	1999-12-17	Expansia Sa	Hydrogenation de 6-alpha-alkylcarboxy methylaryl-1,5-dialkyl uracile
ES2189300T3 (es)	1998-06-26	2003-07-01	Crompton Vinyl Additives Gmbh	Nuevos 6-aminouracilos modificados con nh2 como estabilizadores para polimeros halogenados.
US6177437B1 (en)	1998-09-04	2001-01-23	University Of Massachusetts Medical Center	Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
JP2002538144A (ja) *	1999-03-04	2002-11-12	コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー	抗ウイルス性２，４−ピリミジンジオン誘導体およびその製造方法
KR20000065885A (ko)	1999-04-10	2000-11-15	최승주	항바이러스성 피리미딘다이온 유도체 및 그 제조방법
WO2001023363A1 (fr)	1999-09-29	2001-04-05	Sankyo Company, Limited	Derives de sulfonamide
JP2001114767A (ja)	1999-10-15	2001-04-24	Sumika Fine Chemicals Co Ltd	ピリミジン化合物の製造方法、およびその中間体の製造方法
AR033365A1 (es)	2000-04-17	2003-12-17	Basf Ag	Compuestos benzisotiazol y benzisoxazol 3-heterociclicos sustituidos herbicidas
EA005677B1 (ru)	2000-05-04	2005-04-28	Басф Акциенгезельшафт	Гетероциклилзамещенные фенилсульфамоилкарбоксамиды
WO2002060880A1 (fr)	2001-01-29	2002-08-08	Universite De Geneve	Derives d'acyclonucleosides pyrimidiniques, leur procede de preparation et leur utilisation
JP2002284686A (ja)	2001-03-28	2002-10-03	Sankyo Co Ltd	スルホンアミド化合物を含有する医薬組成物
WO2003029226A1 (en)	2001-09-26	2003-04-10	Basf Aktiengesellschaft	Heterocyclyl substituted phenoxyalkyl-, phenylthioalkyl-, phenylaminoalkyl- and phenylalkyl-sulfamoylcarboxamides
WO2003057677A1 (en)	2002-01-11	2003-07-17	Syddansk Universitet	Anti-retroviral 5,6-disubstituted acyclopyrimidine nucleoside derivatives
US7132467B2 (en)	2002-01-31	2006-11-07	Ciba Specialty Chemicals Corp.	Stabilization of polyolefins in permanent contact with chlorinated water
US20050239054A1 (en)	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
ATE367394T1 (de)	2002-04-26	2007-08-15	Gilead Sciences Inc	Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
WO2004014868A2 (en) *	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
US20050026902A1 (en) *	2003-01-31	2005-02-03	Timothy Maziasz	Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US7947817B2 (en)	2003-06-30	2011-05-24	Roche Molecular Systems, Inc.	Synthesis and compositions of 2'-terminator nucleotides
JP2007512358A (ja)	2003-11-21	2007-05-17	ユニバーシティオブコネチカット	増殖性の病気または感染症の治療に用いる複素環で置換されたオキセタン。
MXPA03011298A (es)	2003-12-08	2005-06-10	Ct Investig Y Estudios Del Ipn	Compuestos 5'-nor-1-homo-n-carbonucleosidos y proceso de obtencion de los mismos.
JP2005212143A (ja)	2004-01-27	2005-08-11	Fuji Photo Film Co Ltd	記録材料
WO2006070292A2 (en)	2004-10-12	2006-07-06	Queen's University At Kingston	Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US7250421B2 (en)	2005-01-31	2007-07-31	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
US20060194821A1 (en)	2005-02-18	2006-08-31	The Brigham And Women's Hospital, Inc.	Compounds inhibiting the aggregation of superoxide dismutase-1
US20060223834A1 (en)	2005-04-04	2006-10-05	Vasu Nair	Diketo acids on nucleobase scaffolds as inhibitors of Flaviviridae
KR101237312B1 (ko) *	2006-02-10	2013-03-04	삼진제약주식회사	피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
WO2007106450A2 (en)	2006-03-10	2007-09-20	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy
FI20065162A0 (fi)	2006-03-13	2006-03-13	Wallac Oy	Terminoivia DNA polymeraasisubstraatteja
AP2514A (en)	2006-07-24	2012-11-23	Korea Res Inst Chem Tech	HIV reverse transcriptase inhibitors
CN101016265A (zh)	2007-03-15	2007-08-15	首都医科大学	一种新型hiv－1逆转录酶抑制剂的制备及其用途
US8119800B2 (en) *	2007-12-21	2012-02-21	Korea Research Institute Of Chemical Technology	Processes for preparing HIV reverse transcriptase inhibitors

2008
- 2008-06-26 TW TW097123922A patent/TW200918507A/zh unknown
- 2008-06-26 CA CA 2692460 patent/CA2692460A1/en not_active Abandoned
- 2008-06-26 AU AU2008271114A patent/AU2008271114A1/en not_active Abandoned
- 2008-06-26 WO PCT/US2008/007925 patent/WO2009005674A2/en active Application Filing
- 2008-06-26 CN CN200880022127.6A patent/CN101784532B/zh active Active
- 2008-06-26 EP EP08779769.2A patent/EP2167476B1/en active Active
- 2008-06-26 KR KR1020107002073A patent/KR101551238B1/ko active IP Right Grant
- 2008-06-26 MX MX2009013804A patent/MX2009013804A/es active IP Right Grant
- 2008-06-26 EA EA200971115A patent/EA200971115A1/ru unknown
- 2008-06-26 JP JP2010514800A patent/JP2010532350A/ja active Pending
- 2008-06-26 US US12/215,450 patent/US8334295B2/en active Active
- 2008-06-26 ES ES08779769.2T patent/ES2533863T3/es active Active
- 2008-06-26 BR BRPI0813269-0A2A patent/BRPI0813269A2/pt not_active IP Right Cessation
- 2008-06-26 AR ARP080102755A patent/AR067181A1/es not_active Application Discontinuation
2010
- 2010-01-04 ZA ZA2010/00023A patent/ZA201000023B/en unknown
2012
- 2012-11-20 US US13/682,729 patent/US20130078256A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AR067181A1 (es)	2009-09-30
ZA201000023B (en)	2011-04-28
CA2692460A1 (en)	2009-01-08
WO2009005674A3 (en)	2009-09-24
MX2009013804A (es)	2010-02-03
US8334295B2 (en)	2012-12-18
EP2167476A2 (en)	2010-03-31
ES2533863T3 (es)	2015-04-15
US20110076276A1 (en)	2011-03-31
WO2009005674A2 (en)	2009-01-08
EA200971115A1 (ru)	2010-04-30
KR20100041799A (ko)	2010-04-22
TW200918507A (en)	2009-05-01
CN101784532B (zh)	2014-10-22
EP2167476B1 (en)	2015-02-25
CN101784532A (zh)	2010-07-21
AU2008271114A1 (en)	2009-01-08
KR101551238B1 (ko)	2015-09-09
JP2010532350A (ja)	2010-10-07
US20130078256A1 (en)	2013-03-28

Publication	Publication Date	Title
BRPI0813269A2 (pt)	2014-12-30	Inibidores de hiv transcriptase reversa
AP2514A (en)	2012-11-23	HIV reverse transcriptase inhibitors
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
NO20161397A1 (no)	2016-09-02	Ikke-nukleosidbaserte revers-transkriptase-inhibitorer
ATE503744T1 (de)	2011-04-15	Nicht-nukleosidische reverse-transkriptase-hemmer
EP2220091A4 (en)	2011-04-27	REVERSE transcriptase inhibitors
IL188615A0 (en)	2008-04-13	Hiv reverse transcriptase inhibitors
ZA200903395B (en)	2010-05-26	Non-nucleoside reverse transcriptase inhibitors
EP2076492A4 (en)	2010-12-22	NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
DK2383271T3 (da)	2013-10-07	Aminoquinoloner som GSK-3-inhibitorer
IL205386A0 (en)	2010-12-30	Non - nucleoside reverse transcriptase inhibitors
EP2217069A4 (en)	2012-03-14	INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
EP2127790A4 (en)	2012-01-04	Drilling apparatus
DE602008001705D1 (de)	2010-08-19	Bohrwerkzeug
EP2116533A4 (en)	2012-01-25	Glucokinase AKTIVATOR
EP2099789A4 (en)	2012-02-15	INHIBITORS OF HIV REPLICATION
EP2143714A4 (en)	2011-09-07	TETRAHYDROISOQUINOLINE COMPOUND
BRPI0810496A2 (pt)	2018-11-06	inibidores de transcriptase reversa de não-nucleosídeo
BRPI0714509A2 (pt)	2014-04-08	Inibidores de transcriptase reversa de não-nucleosídeo.
BRPI0811645A2 (pt)	2014-11-11	Inibidores de transcriptase reversa de não-nucleosídeo
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
ZA200800185B (en)	2009-04-29	Hiv reverse transcriptase inhibitors
DK2221296T3 (da)	2012-09-24	Kondenserede indanforbindelser
DE112006004142A5 (de)	2009-09-03	Turbinenbauteil

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.